{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:02:44Z","timestamp":1756425764647,"version":"3.44.0"},"reference-count":42,"publisher":"BMJ","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DTB"],"published-print":{"date-parts":[[2000,1]]},"abstract":"<jats:p>In 1992, we advised that \"the oral contraceptive of choice for a healthy young woman probably remains a combined preparation containing 30 or 35\u00b5g oestrogen and one of the newer progestogens\" (i.e. desogestrel, gestodene, norgestimate).1 In 1995, evidence emerged suggesting that combined oral contraceptives containing desogestrel or gestodene were associated with a risk of venous thromboembolism about twice that of pills containing other progestogens,2 and the Committee on Safety of Medicines (CSM) advised that desogestrel- and gestodene-containing pills should be used only by women who were intolerant of other combined oral contraceptives and prepared to accept an increased risk of venous thromboembolism. Following an appeal by the drug manufacturers to the UK Medicines Commission, this advice has been modified to state that, provided women are fully informed of the increased risks, \"it should be a matter of clinical judgement and personal choice which type of oral contraceptive should be prescribed\".3 Here, we discuss the evidence and events leading to the latest advice, reconsider our previous recommendations, and discuss other cardiovascular problems that may be associated with oral contraceptive pills.<\/jats:p>","DOI":"10.1136\/dtb.2000.3811-a","type":"journal-article","created":{"date-parts":[[2008,7,18]],"date-time":"2008-07-18T16:15:40Z","timestamp":1216397740000},"page":"1.2-5","source":"Crossref","is-referenced-by-count":8,"title":["Oral contraceptives and cardiovascular risk"],"prefix":"10.1136","volume":"38","member":"239","published-online":{"date-parts":[[2000,1,1]]},"reference":[{"key":"2025082800234424000_38.1.1-a.1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/dtb.30.11.41","article-title":"Starting oral contraceptives - which, when and how?","volume":"30","year":"1992","journal-title":"DTB"},{"key":"2025082800234424000_38.1.1-a.2","unstructured":"Department of Health . New Advice on Oral Contraceptives London: Department of Health 95\\489 1995."},{"key":"2025082800234424000_38.1.1-a.3","first-page":"12","article-title":"Combined oral contraceptives containing desogestrel or gestodene and the risk of venous thromboembolism","volume":"25","year":"1999","journal-title":"Curr Probl Pharmacovigilance"},{"key":"2025082800234424000_38.1.1-a.4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1136\/bmj.2.5703.203","article-title":"Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs","volume":"2","author":"Inman","year":"1970","journal-title":"BMJ"},{"key":"2025082800234424000_38.1.1-a.5","unstructured":"WHO Scientific Group on Cardiovascular Disease and Steroid Hormone Contraception . Cardiovascular disease and steroid hormone contraception: report of a WHO scientific group WHO Technical Report Series; 877 Geneva: World Health Organization 1998."},{"key":"2025082800234424000_38.1.1-a.6","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/S0140-6736(95)91929-5","article-title":"Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen","volume":"346","author":"Bloemenkamp","year":"1995","journal-title":"Lancet"},{"key":"2025082800234424000_38.1.1-a.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)91929-5"},{"key":"2025082800234424000_38.1.1-a.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)91928-7"},{"key":"2025082800234424000_38.1.1-a.9","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(95)91927-9","article-title":"Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease","volume":"346","year":"1995","journal-title":"Lancet"},{"key":"2025082800234424000_38.1.1-a.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)91136-7"},{"key":"2025082800234424000_38.1.1-a.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)07496-X"},{"key":"2025082800234424000_38.1.1-a.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-7824(98)00014-6"},{"key":"2025082800234424000_38.1.1-a.13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.319.7206.387"},{"key":"2025082800234424000_38.1.1-a.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)01257-X"},{"key":"2025082800234424000_38.1.1-a.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-7824(97)00119-4"},{"key":"2025082800234424000_38.1.1-a.16","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/14.6.1493"},{"key":"2025082800234424000_38.1.1-a.17","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/14.6.1500"},{"key":"2025082800234424000_38.1.1-a.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)90286-0"},{"key":"2025082800234424000_38.1.1-a.19","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.192707.x"},{"key":"2025082800234424000_38.1.1-a.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)06092-4"},{"key":"2025082800234424000_38.1.1-a.21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.313.7065.1127"},{"key":"2025082800234424000_38.1.1-a.22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1056\/NEJM197807062990104","article-title":"Serum high-density-lipoprotein cholesterol in women using oral contraceptives, estrogens and progestins","volume":"299","author":"Bradley","year":"1978","journal-title":"N Engl J Med"},{"key":"2025082800234424000_38.1.1-a.23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3109\/00016347909157230","article-title":"Effects of three different combinations of ethinyl estradiol and levonorgestrel on plasma lipids and high density lipoproteins","volume":"88","author":"Larsson-Cohn","year":"1979","journal-title":"Acta Obstet Gynecol Scand"},{"key":"2025082800234424000_38.1.1-a.24","first-page":"67","article-title":"The effect on serum lipids and lipoproteins of three combined oral contraceptives containing norgestimate, gestodene and desogestrel","volume":"22","author":"Gillmer","year":"1996","journal-title":"Br J Fam Plann"},{"key":"2025082800234424000_38.1.1-a.25","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/S0140-6736(97)02358-1","article-title":"Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"2025082800234424000_38.1.1-a.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)02358-1"},{"key":"2025082800234424000_38.1.1-a.27","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-7824(97)00118-2"},{"key":"2025082800234424000_38.1.1-a.28","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1136\/bmj.318.7198.1579","article-title":"Oral contraceptives and myocardial infarction: the results of the MICA case-control study","volume":"318","author":"Dunn","year":"1999","journal-title":"BMJ"},{"key":"2025082800234424000_38.1.1-a.29","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/j.1471-0528.1998.tb10235.x","article-title":"Risk of myocardial infarction, angina and stroke in users of oral contraceptives: an updated analysis of a cohort study","volume":"105","author":"Mant","year":"1998","journal-title":"Br J Obstet Gynaecol"},{"key":"2025082800234424000_38.1.1-a.30","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1161\/01.STR.28.2.280","article-title":"Incidence of stroke and myocardial infarction in women of reproductive age","volume":"28","author":"Petitti","year":"1997","journal-title":"Stroke"},{"key":"2025082800234424000_38.1.1-a.31","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.28.2.280"},{"key":"2025082800234424000_38.1.1-a.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)12393-8"},{"key":"2025082800234424000_38.1.1-a.33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)01013-2"},{"key":"2025082800234424000_38.1.1-a.34","unstructured":"Huezo CM Carignan CS . Medical and Service Delivery Guidelines for Family Planning . Second edition London: International Planned Parenthood Federation Publications 1997."},{"key":"2025082800234424000_38.1.1-a.35","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0010-7824(93)90034-5","article-title":"Effect of four combined oral contraceptives on blood pressure in the pill-free interval","volume":"47","author":"Nichols","year":"1993","journal-title":"Contraception"},{"key":"2025082800234424000_38.1.1-a.36","first-page":"727","article-title":"Mortality among oral-contraceptive users","volume":"ii","year":"1977","journal-title":"Lancet"},{"key":"2025082800234424000_38.1.1-a.37","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/bmj.294.6579.1057","article-title":"Malignant hypertension in women of childbearing age and its relation to the contraceptive pill","volume":"294","author":"Lim","year":"1987","journal-title":"BMJ"},{"key":"2025082800234424000_38.1.1-a.38","unstructured":"Poulter NR . Oral contraceptives and blood pressure Evidence-Guided Prescribing of the Pill Hannaford PC Webb AMC . The Parthenon Publishing Group. New York 1996."},{"key":"2025082800234424000_38.1.1-a.39","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/bmj.318.7175.13","article-title":"Migraine and stroke in young women: case-control study","volume":"318","author":"Chang","year":"1999","journal-title":"BMJ"},{"key":"2025082800234424000_38.1.1-a.40","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.318.7175.13"},{"key":"2025082800234424000_38.1.1-a.41","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0010-7824(98)00041-9","article-title":"Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives","volume":"57","year":"1998","journal-title":"Contraception"},{"key":"2025082800234424000_38.1.1-a.42","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-7824(98)00041-9"}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2000.3811-a","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T07:23:58Z","timestamp":1756365838000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2000.3811-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,1]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2000,1,1]]},"published-print":{"date-parts":[[2000,1]]}},"alternative-id":["10.1136\/dtb.2000.3811-a"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2000.3811-a","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2000,1]]}}}